Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrystal Amber Regulatory News (CRS)

Share Price Information for Crystal Amber (CRS)

Share Price is delayed by 15 minutes
Get Live Data
104.00    0.00 (0.00%)
Bid:
102.00
Ask:
106.00
Spread: 4.00 (3.922%)
Market Cap: £61.92m
CRS Live PriceLast checked at - London Stock Exchange

Intraday Crystal Amber Share Chart

Extension to Share Buyback Programme

2 Apr 2024 13:30

RNS Number : 9907I
Crystal Amber Fund Limited
02 April 2024
 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 to the extent it forms part of the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (as amended by virtue of the European Union (Withdrawal Agreement) Act 2020). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

2 April 2024

 

Crystal Amber Fund Limited

("Crystal Amber Fund", the "Company" or the "Fund")

 

Extension to Share Buyback Programme

 

Crystal Amber Fund announces that it will continue its share buyback programme for the period to 30 June 2024. Since 8 December 2023, £5 million has been utilised in the programme and from now until 30 June 2024, the Company intends to continue to conduct on-market purchases under the share buyback programme to repurchase ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") up to an aggregate amount of £2.5 million, pursuant to the authority obtained at the Company's annual general meeting on 22 November 2023 (the "Buyback").

 

The Company has appointed Winterflood Securities Limited ("Winterflood") to execute and manage the Buyback and has given an irrevocable instruction to Winterflood to make market purchases of Ordinary Shares on its behalf, independently of the Company. Winterflood will make its trading decisions in relation to the Ordinary Shares independently of and uninfluenced by the Company with such trading decisions being in line with the terms of the Buyback.

 

The maximum price which may be paid by the Company per Ordinary Share shall not be more than the higher of:

a.  105 per cent of the average of the middle market quotations for an Ordinary Share as derived from the AIM market of the London Stock Exchange plc for the five business days immediately preceding the day on which the purchase is made; and

b. the value of an Ordinary Share calculated on the basis of the higher of the price quoted for (i) the last independent trade of and (ii) the highest current independent bid for the Ordinary Shares.

 

The Company has determined that it will not rely on the safe harbour conditions for trading set out in Article 5 of EU Market Abuse Regulation (2014/596/EU) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018) ("UK MAR") and, accordingly, the Company will not benefit from the exemption contained in Article 5 of UK MAR, given the limited liquidity in the Ordinary Shares and limitations that it would impose on the number of Ordinary Shares that can be purchased. Therefore, the Company may purchase Ordinary Shares pursuant to the Buyback on any trading day materially in excess of 25 per cent of the average daily volume in the 20 trading days preceding the date on which the purchase is carried out, being the limit laid down in Article 5(1) of UK MAR.

 

There is no guarantee that the Buyback programme will be implemented in full or that any purchases will be made. The Company reserves the right to bring a halt to the Buyback under circumstances that it deems to be appropriate and in accordance with relevant law and regulation.

 

The Company will make further announcements in due course following any share purchases conducted through the Buyback.

 

The Company confirms that, other than as disclosed in this announcement, it is not currently in possession of any unpublished inside information.

 

For further enquiries please contact:

 

Crystal Amber Fund Limited

Chris Waldron (Chairman)

Tel: 01481 742 742

www.crystalamber.com

 

Allenby Capital Limited - Nominated Adviser

Jeremy Porter/ Dan Dearden-Williams

Tel: 020 3328 5656

 

Winterflood Investment Trusts - Broker

Joe Winkley/Neil Langford

Tel: 020 3100 0160

 

Crystal Amber Advisers (UK) LLP - Investment Adviser

Richard Bernstein

Tel: 020 7478 9080

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFFFSFIFIIS
Date   Source Headline
22nd Dec 20254:48 pmRNSTransaction in Own Shares and Total Voting Rights
19th Dec 20255:04 pmRNSTransaction in Own Shares and Total Voting Rights
19th Dec 20255:04 pmRNSTransaction in Own Shares and Total Voting Rights
18th Dec 20254:57 pmRNSTransaction in Own Shares and Total Voting Rights
18th Dec 20254:57 pmRNSTransaction in Own Shares and Total Voting Rights
17th Dec 20255:57 pmRNSTransaction in Own Shares and Total Voting Rights
17th Dec 20254:15 pmRNSMonthly Net Asset Value
16th Dec 20255:19 pmRNSTransaction in Own Shares and Total Voting Rights
15th Dec 20256:18 pmRNSTransaction in Own Shares and Total Voting Rights
15th Dec 20257:00 amRNSTransaction in Own Shares and Total Voting Rights
11th Dec 20255:43 pmRNSTransaction in Own Shares and Total Voting Rights
11th Dec 20257:00 amRNSDirector/PDMR Shareholding
9th Dec 20255:42 pmRNSTransaction in Own Shares and Total Voting Rights
8th Dec 20255:36 pmRNSTransaction in Own Shares and Total Voting Rights
5th Dec 20255:00 pmRNSTransaction in Own Shares and Total Voting Rights
4th Dec 20255:41 pmRNSTransaction in Own Shares and Total Voting Rights
3rd Dec 202510:17 amRNSShare Buyback Programme
2nd Dec 20251:08 pmRNSResult of AGM
1st Dec 20257:00 amRNSTransaction in Own Shares and Total Voting Rights
24th Nov 20256:07 pmRNSTransaction in Own Shares and Total Voting Rights
21st Nov 20256:30 pmRNSTransaction in Own Shares and Total Voting Rights
20th Nov 20257:00 amRNSShare Buyback Programme
20th Nov 20257:00 amRNSMonthly Net Asset Value
18th Nov 20257:00 amRNSDirector/PDMR Shareholding
17th Nov 20256:05 pmRNSTransaction in Own Shares and Total Voting Rights
17th Nov 20255:59 pmRNSHolding(s) in Company
14th Nov 20256:11 pmRNSTransaction in Own Shares and Total Voting Rights
14th Nov 20257:05 amRNSProposed change of strategy and investment manager
13th Nov 20255:39 pmRNSTransaction in Own Shares and Total Voting Rights
6th Nov 20257:00 amRNSNotice of AGM
31st Oct 20255:30 pmRNSTotal Voting Rights
27th Oct 20256:13 pmRNSTransaction in Own Shares and Total Voting Rights
24th Oct 20259:51 amRNSMonthly Net Asset Value
24th Oct 20259:50 amRNSMonthly Net Asset Value
24th Oct 20259:48 amRNSMonthly Net Asset Value
24th Oct 20259:47 amRNSMonthly Net Asset Value
20th Oct 20256:29 pmRNSTransaction in Own Shares and Total Voting Rights
20th Oct 202511:11 amRNSShare Buyback Programme
17th Oct 20257:00 amRNSFinal Results
16th Oct 20257:00 amRNS-RInvestor Presentation by Morphic Medical Inc
7th Oct 20257:00 amRNS-RInvestor Presentation by Morphic Medical Inc
30th Sep 20255:00 pmRNSTransaction in Own Shares and Total Voting Rights
29th Sep 20255:04 pmRNSTransaction in Own Shares and Total Voting Rights
25th Sep 20255:26 pmRNSTransaction in Own Shares and Total Voting Rights
22nd Sep 20257:00 amRNSTransaction in Own Shares and Total Voting Rights
17th Sep 20257:00 amRNSTransaction in Own Shares and Total Voting Rights
15th Sep 20257:00 amRNS-RMorphic Medical Inc. appoints new CFO
10th Sep 20255:21 pmRNSTransaction in Own Shares and Total Voting Rights
4th Sep 20255:29 pmRNSTransaction in Own Shares and Total Voting Rights
2nd Sep 20255:31 pmRNSTransaction in Own Shares and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.